A new breakthrough from the University of Saskatchewan could potentially reduce the duration of calving season for beef producers. Cetrorelix, a hormone drug primarily utilized in human IVF treatments, has shown promising results in cattle reproduction. Dr. Jaswant Singh, along with graduate students Dylan Farmer and Carlos Leonardi, discovered the drug’s efficacy in synchronizing ovulation in cows, leading to simultaneous pregnancies and births.
The innovative drug offers a more efficient method of managing calving periods, potentially cutting labor costs and improving livestock management. Garner Deobald, a beef rancher and marketing manager at BoviGen Genetic Services, expressed keen interest in incorporating Cetrorelix into their breeding practices if proven effective. The drug’s potential benefits extend to enhancing artificial insemination techniques, enabling better genetic selection and calf production insights.
The University of Saskatchewan has filed a patent for Cetrorelix and is collaborating with pharmaceutical companies to bring it to market. Dr. Singh envisions widespread adoption of the drug globally, emphasizing its affordability and regulatory progress. The promising results of Cetrorelix in animal trials suggest a significant advancement in cattle breeding practices and potential benefits for livestock producers worldwide.
